Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
In this section, we usually try to help investors determine whether Pharmacy Chain 36.6 is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Pharmacy Chain 36.6 has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.
Show me the analysis anyway
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Pharmacy Chain 36.6. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
Pharmacy Chain 36.6's
is considered below, and whether this is a fair price.
Price based on past earnings
Pharmacy Chain 36.6's earnings available for a low price, and how does
this compare to other companies in the same industry?
Pharmacy Chain 36.6 has negative assets, we can't compare the value of its assets to the Europe Consumer Retailing industry average.
When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Pharmacy Chain 36.6's regulatory filings and announcements.
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Pharmacy Chain 36.6 has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Consumer Retailing industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Pharmacy Chain 36.6
expected to grow at an
Unable to compare Pharmacy Chain 36.6's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Pharmacy Chain 36.6's earnings growth to the Russian Federation market average as no estimate data is available.
Unable to compare Pharmacy Chain 36.6's revenue growth to the Russian Federation market average as no estimate data is available.
Unable to determine if Pharmacy Chain 36.6 is high growth as no earnings estimate data is available.
Unable to determine if Pharmacy Chain 36.6 is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Pharmacy Chain 36.6's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
Pharmacy Chain 36.6
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Pharmacy Chain 36.6's finances.
The net worth of a company is the difference between its assets and liabilities.
Pharmacy Chain 36.6's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
Pharmacy Chain 36.6's long term commitments exceed its cash and other short term assets.
This treemap shows a more detailed breakdown of
Pharmacy Chain 36.6's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
High level of physical assets or inventory.
Pharmacy Chain 36.6 has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
Mr. Vladimir Vazhaevich Kintsurashvili serves as General Director & Chairman of the Management Board at Open Joint Stock Company Pharmacy Chain 36.6. Mr. Kintsurashvili served as a General Manager of Open Joint Stock Company Pharmacy Chain 36.6 and served as its Director since November 27, 2013. Mr. Kintsurashvili is the Co-Owner of LLC Apteka A.V.E. Mr. Kintsurashvili headed the pharmacy chain A5 (OJSC TS Aptechka) from 2006 to 2011. He was released from the post in 2011. After he left A5, he and partner Ivan Saganelidze began to develop their own pharmacy chain, A.v.e., which was set up initially with twenty outlets under the brand name Alphega. In September 2012, A.v.e. joined up with the Moscow-based discounter Gorzdrav. Gorzdrav's owners, Igor Zhibarovsky and Temur Shakaya, obtained 45% of A.v.e. in equal proportions. He
Insufficient data for Vladimir to compare compensation growth.
Insufficient data for Vladimir to establish whether their remuneration is reasonable compared to companies of similar size in .
General Director & Chairman of the Management Board
General Director & Member of the Management Board
First Deputy General Director
Chief Financial Officer
Chief Operational Officer
Director of Corporate Finance & Member of the Management Board
Should You Be Concerned About Public Joint-Stock Company Pharmacy Chain 366's (MCX:APTK) Shareholders?
In this article, I'm going to take a look at Public Joint-Stock Company Pharmacy Chain 366’s (MISX:APTK) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors. … Private Company Ownership Potential investors in APTK should also look at another important group of investors: private companies, with a stake of 68.93%, who are primarily invested because of strategic and capital gain interests. … Thus, potential investors should look into these business relations and check how it can impact long-term shareholder returns.Next Steps: Institutional ownership level and composition in APTK is not high nor active enough to significantly impact its investment thesis.
Does Public Joint-Stock Company Pharmacy Chain 366 (MCX:APTK) Have Enough Money Left To Grow?
Pharmacy Chain 36.6 may need to come to market again, but the question is, when? … View our latest analysis for Pharmacy Chain 36.6 What is cash burn? … MISX:APTK Income Statement Apr 24th 18 When will Pharmacy Chain 36.6 need to raise more cash?
What Investors Should Know About Public Joint-Stock Company Pharmacy Chain 366's (MCX:APTK) Financial Strength
With this increase in debt, APTK currently has RUРУБ585.00M remaining in cash and short-term investments for investing into the business. … Moving onto cash from operations, its small level of operating cash flow means calculating cash-to-debt wouldn't be too useful, though these low levels of cash means that operational efficiency is worth a look. … Maintaining a high level of debt, while revenues are still below costs, can be dangerous as liquidity tends to dry up in unexpected downturns.Next Steps: With a high level of debt on its balance sheet, APTK could still be in a financially strong position if its cash flow also stacked up.
Public Joint-Stock Company Pharmacy Chain 36.6 operates pharmacies in Russia. Its pharmacies offer approximately 30 categories of goods for health and beauty. As of December 31, 2017, it operated 1601 pharmacies under the 36.6 brand name in the regions of Moscow, St. Petersburg, and Leningrad. The company was founded in 1991 and is based in Moscow, Russia.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.